• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Enovis Corporation filed SEC Form 8-K: Leadership Update

    11/14/25 4:05:37 PM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    false 0001420800 0001420800 2025-11-07 2025-11-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): November 7, 2025

     

     

     

    Enovis Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-34045   54-1887631
    (State or other jurisdiction   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification No.)

     

    2711 Centerville Road, Suite 400

    Wilmington, DE 19808

    (Address of principal executive offices) (Zip Code)

     

    (302) 252-9160

    (Registrant’s telephone number, including area code)

     

    Not applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   ENOV   New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On November 7, 2025, Daniel A. Pryor and Enovis Corporation (the “Company”) agreed that he would step down from his position as an executive officer of the Company as of such date, and remain as an employee of the Company in an advisory role through March 31, 2026 (the “Departure Date”). Mr. Pryor’s departure is part of a restructuring of management roles at the Company, which included the elimination of his former position of Executive Vice President, Strategy and Business Development, and constitutes a termination without cause under the terms of Mr. Pryor’s employment agreement with the Company, dated January 1, 2011 (the “Employment Agreement”).

     

    In connection therewith, the Company and Mr. Pryor entered into a Separation and General Release Agreement, dated November 14, 2025 (the “Separation Agreement”), pursuant to which Mr. Pryor will remain with the Company until the Departure Date and provide transition services. Pursuant to the Separation Agreement, Mr. Pryor will continue to be paid his current base salary and be entitled to the same benefits applicable to his employment until the Departure Date. Mr. Pryor will remain eligible to receive a cash bonus for 2025 in accordance with the terms of the Company’s annual incentive plan and his Company equity awards will continue to vest in accordance with the terms of the relevant award agreements through the Departure Date, but he will not receive any further equity grants under the Company’s long-term incentive plans. Following the Departure Date, and subject to Mr. Pryor’s compliance with the terms of the Separation Agreement, Mr. Pryor will receive cash payments equal to the sum of (i) his annual base salary as of the Departure Date, plus (ii) the greater of (x) his target annual cash incentive in effect for the year or (y) the average of the largest two annual cash incentives received during the three years prior to the Departure Date, as provided for in the Employment Agreement. Mr. Pryor will also receive a Partial Year Bonus (as defined in the Employment Agreement) for 2026, health benefit continuation for twelve months from the Departure Date, and outplacement assistance subject to a cap of $75,000. The Separation Agreement includes a general release and waiver from Mr. Pryor. The foregoing summary of the terms of Mr. Pryor’s Separation Agreement is qualified in its entirety by the full text of the agreement, which is expected to be filed with the Company’s next Annual Report on Form 10-K.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 14, 2025    
       
      ENOVIS CORPORATION
         
      By: /s/ Bradley J. Tandy
      Name: Bradley J. Tandy
      Title: Senior Vice President and Chief Legal Officer

     

     

    Get the next $ENOV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    6/26/2023$70.00Buy
    Needham
    More analyst ratings

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JMP Securities initiated coverage on Enovis Corporation with a new price target

    JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

    10/3/24 7:29:21 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    JP Morgan initiated coverage on Enovis Corporation with a new price target

    JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00

    6/13/24 7:06:52 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Stephens initiated coverage on Enovis Corporation with a new price target

    Stephens initiated coverage of Enovis Corporation with a rating of Overweight and set a new price target of $72.00

    2/13/24 6:34:49 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lalor Angela S was granted 742 shares, increasing direct ownership by 4% to 21,295 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    10/1/25 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Executive Officer Mcdonald Damien bought $199,973 worth of shares (6,457 units at $30.97), increasing direct ownership by 7% to 102,753 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    9/11/25 5:59:16 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SVP and Chief Legal Officer Tandy Bradley J bought $100,512 worth of shares (3,200 units at $31.41), increasing direct ownership by 8% to 43,515 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/25/25 6:30:04 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    SEC Filings

    View All

    Enovis Corporation filed SEC Form 8-K: Leadership Update

    8-K - Enovis CORP (0001420800) (Filer)

    11/14/25 4:05:37 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Enovis Corporation

    10-Q - Enovis CORP (0001420800) (Filer)

    11/6/25 6:25:16 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Enovis CORP (0001420800) (Filer)

    11/6/25 6:09:24 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Mcdonald Damien bought $199,973 worth of shares (6,457 units at $30.97), increasing direct ownership by 7% to 102,753 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    9/11/25 5:59:16 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SVP and Chief Legal Officer Tandy Bradley J bought $100,512 worth of shares (3,200 units at $31.41), increasing direct ownership by 8% to 43,515 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/25/25 6:30:04 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    SVP, Chief Financial Officer Berry Phillip Benjamin (Ben) bought $74,275 worth of shares (2,500 units at $29.71), increasing direct ownership by 2% to 116,729 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/20/25 5:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enovis Announces Third Quarter 2025 Results

    Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 3, 2025. The Company will host an investor conference call and live webcast to discus

    11/6/25 6:01:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences

    Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, will be made available on the "Investors" section of Enovis' website at www.enovis.com. Additionally, the company also announced it will participate in the following investor conferences: UBS Global Healthcare Conference: Damien McD

    10/24/25 4:11:14 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million

    Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners, a multi-family asset management firm based in Chicago, for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million, and up to $15 million payable in the future upon the achievement of certain milestones. "This transaction represents a positive outcome for Enovis, our Dr. Comfort business, and Promus Equity Partners," said Damien McDonald, Enovis' Chief Executive Officer. "The sale sharpens our fo

    10/8/25 8:15:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    View All

    Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

    Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

    4/2/25 6:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

    NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

    1/7/25 6:19:00 PM ET
    $ARCH
    $CART
    $CEIX
    Coal Mining
    Energy
    Real Estate
    Industrial Specialties

    Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

    WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in le

    9/9/24 3:50:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Financials

    Live finance-specific insights

    View All

    Enovis Announces Third Quarter 2025 Results

    Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 3, 2025. The Company will host an investor conference call and live webcast to discus

    11/6/25 6:01:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences

    Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, will be made available on the "Investors" section of Enovis' website at www.enovis.com. Additionally, the company also announced it will participate in the following investor conferences: UBS Global Healthcare Conference: Damien McD

    10/24/25 4:11:14 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Second Quarter 2025 Results

    Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2025 Financial Results Enovis' second-quarter net sales of $565 million grew 7% on a reported basis and 5% on an organic basis from the same quarter

    8/7/25 6:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enovis Corporation

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    11/14/24 1:28:31 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    4/5/24 12:21:51 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    2/14/24 10:04:36 AM ET
    $ENOV
    Industrial Specialties
    Health Care